Document:

EX-10.1

 Exhibit 10.1 

AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT 

This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT
AGREEMENT (“Agreement”) is entered into effective February 1, 2022 (“Effective Date”), by and between Mark Gergen (“Executive”) and
Poseida Therapeutics, Inc. (“Company”). 
 The Executive has been employed by the Company pursuant to that certain
Executive Employment Agreement dated as of February 19, 2018 (“Prior Agreement”); 
 The Company desires to
continue to employ Executive and, in connection with such continued employment, to compensate Executive for Executive’s personal services to the Company pursuant this Agreement, which shall amend, supersede and replace that certain Prior
Agreement; and 
 Executive desires to continue to provide personal services to the Company in return for certain compensation. 

Accordingly, in consideration of the mutual promises and covenants contained herein, the parties agree to the following: 

1.        EMPLOYMENT BY THE
COMPANY. 

1.1    At-Will Employment. Executive shall be employed
by the Company on an “at will” basis, meaning either the Company or Executive may terminate Executive’s employment at any time, with or without cause or advanced notice. Any contrary representations that may have been made to
Executive shall be superseded by this Agreement. This Agreement shall constitute the full and complete agreement between Executive and the Company on the “at will” nature of Executive’s employment with the Company, which may be
changed only in an express written agreement signed by Executive and a duly authorized officer of the Company. 

1.2    Position. Subject to the terms set forth herein, the Company agrees to employ Executive
in the position of Chief Executive Officer (“CEO”), and Executive hereby accepts such employment. 

1.3    Duties. As CEO, Executive will report to the Company’s Board of Directors
(the “Board”) and/or its designee, performing such duties as are normally associated with his position and such duties as are assigned to him from time to time, subject to the oversight and direction of the Board or its
designee, including work for or on behalf of affiliates of the Company such as its parent, subsidiaries or other group affiliates (together, the “Affiliates”). During the term of Executive’s employment with the Company,
Executive will work on a full-time basis for the Company and will devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company. Executive shall perform Executive’s
duties under this Agreement principally out of the Company’s corporate headquarters in San Diego, California. In addition, Executive shall make such business trips to such places as may be necessary or advisable for the efficient operations of
the Company. 
 1.4    Company Policies and Benefits. The employment relationship between the
parties shall also be subject to the Company’s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from time to time in the Company’s sole discretion. Executive will be eligible to participate on the
same basis as similarly situated employees in the Company’s benefit plans in effect from time to time during his employment. All matters of eligibility for coverage or benefits under any benefit plan shall be determined in accordance with the
provisions of such plan. The Company reserves the right to change, alter, or terminate any benefit plan in its sole discretion. Notwithstanding the foregoing, in the event that the terms of this Agreement differ from or are in conflict with the
Company’s general employment policies or practices, this Agreement shall control. 

2.        COMPENSATION. 

2.1    Salary. Executive shall receive for Executive’s services to be rendered under this
Agreement an initial base salary of $575,000 on an annualized basis, subject to review and adjustment by the Company in its sole discretion, payable subject to standard federal and state payroll withholding requirements in accordance with the
Company’s standard payroll practices (“Base Salary”). 

  
 1. 

 2.2    Annual Incentive Compensation. During the
period Executive employed with the Company, Executive shall be eligible to earn for Executive’s services to be rendered under this Agreement a discretionary annual incentive compensation in the form of a cash bonus of up to fifty-five percent
(55%) of earned Base Salary (“Target Amount”), based on achievement of individual and corporate performance targets, metrics and/or
management-by-objectives (“MBOs”) to be determined and approved by the Company’s Board or the Compensation Committee thereof. Annual
incentive compensation is paid on an annual basis, after the close of the fiscal year and after determination by the Board (or the Compensation Committee thereof) of (i) the level of achievement of the applicable individual and corporate
performance targets, metrics and/or MBOs, and (ii) the amount of the annual incentive compensation earned by Executive (if any). No annual incentive compensation is guaranteed and, in addition to the other conditions for earning such
compensation, Executive must remain an employee in good standing of the Company (or one of its Affiliates) on the scheduled annual incentive compensation payment date in order to be eligible for any annual incentive compensation. This annual
incentive compensation program will be the only incentive compensation, commissions, or other bonus program that will apply to Executive. The annual period over which performance is measured for purposes of this bonus is January 1 through
December 31. 
 2.3    Equity Award. Subject to approval by the Board (or an authorized
committee thereof), Executive will receive an equity award (“New Equity Award”). The New Equity Award will be delivered as a combination of an option to purchase 518,500 shares of the
Company’s common stock (the “Option”) and restricted stock units to be issued 357,200 shares of the Company’s common stock (the “RSU”). The New Equity Award will be granted effective as of
the first trading day of the month following the Effective Date, unless the Effective Date coincides with the first trading day of the month in which case the New Equity Award will be granted effective as of the Effective Date or, in either case, as
soon as administratively practicable thereafter. The New Equity Award is subject to the Company’s 2020 Equity Incentive Plan (the “Plan”) and the Company’s standard forms of stock option agreement and restricted
stock unit award agreement, as applicable. 
 The Option shall be an incentive stock option to the maximum extent permissible under
Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”). The Option shall have an exercise price per share equal to the closing price of the Company’s common stock as reported on the Nasdaq Stock
Market on the date of grant. The Option shares shall vest over time, subject to Executive’s continuous service to the Company on each applicable vesting date(s), as follows: (i) twelve and a half percent (12.5%) of the shares subject to
the Option shall vest on the six-month anniversary of the specified vesting commencement date and (ii) the remaining shares shall vest in 42 consecutive equal monthly installments thereafter. 

The RSU shares shall vest over time, subject to Executive’s continuous service to the Company on each applicable vesting date(s), as
follows: twenty-five percent (25%) of the shares subject to the RSU shall vest on each of the first four anniversaries of the specified vesting commencement date. 

2.4    Expense Reimbursement. The Company will reimburse Executive for reasonable business expenses
in accordance with the Company’s standard expense reimbursement policy, as the same may be modified by the Company from time to time. For the avoidance of doubt, to the extent that any reimbursements payable to Executive are subject to the
provisions of Section 409A of the Code: (a) any such reimbursements will be paid no later than December 31 of the year following the year in which the expense was incurred, (b) the amount of expenses reimbursed in one year
will not affect the amount eligible for reimbursement in any subsequent year, and (c) the right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. 

3.    PROPRIETARY INFORMATION, INVENTIONS, AND
NON-COMPETITION OBLIGATIONS. As a condition of Executive’s continued employment, Executive agrees to continue to abide by Executive’s
previously executed Employee Proprietary Information and Invention Assignment Agreement attached as Exhibit A (“Proprietary Information Agreement”), which may be amended by the parties from time to time without regard to this
Agreement. The Proprietary Information Agreement contains provisions that are intended by the parties to survive and do survive termination of this Agreement. During Executive’s employment by the Company, Executive will not, without the
express written consent of the Company, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor, investor, joint venture, associate, representative or consultant of any person or entity engaged in, or
planning or preparing to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or its Affiliates; provided, however, that Executive may purchase or otherwise acquire up to (but not
more than) one percent (1%) of any class of securities of any enterprise (without participating 

  
 2. 

 
in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. In addition, Executive will be subject to certain restrictions (including
restrictions continuing after Executive’s employment ends) under the terms of Executive’s Proprietary Information Agreement. 

4.    OUTSIDE ACTIVITIES DURING
EMPLOYMENT. Throughout Executive’s employment by the Company, Executive may engage in civic and
not-for-profit activities so long as such activities do not interfere with the performance of Executive’s duties hereunder or present a conflict of interest with
the Company or its Affiliates. Subject to the restrictions set forth herein, and only with prior written disclosure to and consent of the Board, Executive may engage in other types of business or public activities. The Board may withdraw such
consent, if the Board determines, in its sole discretion, that such activities compromise or threaten to compromise the Company’s or its Affiliates’ business interests or conflict with Executive’s duties to the Company or its
Affiliates. This restriction shall not, however, preclude Executive (i) from owning less than one percent (1%) of the total outstanding shares of a publicly traded company, or (ii) from employment or service in any capacity with Affiliates
of the Company. 
 5.    NO CONFLICT WITH
EXISTING OBLIGATIONS. Executive represents that Executive’s performance of all the terms of this Agreement does not and will not breach any agreement or obligation of any kind
made prior to Executive’s employment by the Company, including agreements or obligations Executive may have with prior employers or entities for which Executive has provided services. Executive has not entered into, and Executive agrees that
Executive will not enter into, any agreement or obligation, either written or oral, in conflict herewith. In Executive’s work for the Company and its Affiliates, Executive will be expected not to make any unauthorized use or disclosure of any
confidential information or materials, including trade secrets, or any former employer or other third party; and not to violate any lawful agreement that Executive may have with any third party. By signing this Agreement, Executive represents that
Executive is able to perform Executive’s job duties within these guidelines, and Executive is not in unauthorized possession or control of any confidential documents, information, or other property of any former employer or third party. In
addition, Executive represents that Executive has disclosed to the Company in writing any agreement Executive may have with any third party (e.g., a former employer) which may limit Executive’s ability to perform Executive’s duties
to the Company or its Affiliates or which could present a conflict of interest with the Company or its Affiliates, including but not limed to disclosure (and a copy) or any contractual restrictions on solicitations or competitive activities. 

6.    SEVERANCE AND CHANGE IN
CONTROL PLAN. During Executive’s employment with the Company, Executive will be eligible to participate in the Company’s Severance and Change in Control Plan. As a
condition to Executive’s participation therein, Executive shall be required to execute a Participation Agreement for the Severance and Change in Control Plan. The Severance and Change in Control Plan and Executive’s participation therein
may be modified, amended and/or terminated at any time in the Company’s discretion. The parties acknowledge that Executive’s employment relationship with the Company is at-will. The provisions of the
Severance and Change in Control Plan govern the amount of compensation, if any, to be provided to Executive upon termination of employment and do not alter this at-will status. 

7.    COOPERATION WITH COMPANY AFTER
TERMINATION OF EMPLOYMENT. Following termination of Executive’s employment for any reason, Executive agrees to cooperate fully with the Company in connection
with its actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of Executive’s
employment by the Company. Such cooperation includes, without limitation, making Executive available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions
and trial testimony. In addition, for six months after Executive’s employment with the Company ends for any reason, Executive agrees to cooperate fully with the Company in all matters relating to the transition of Executive’s work and
responsibilities on behalf of the Company, including, but not limited to, any present, prior or subsequent relationships and the orderly transfer of any such work and institutional knowledge to such other persons as may be designated by the Company.
The Company will reimburse Executive for reasonable out-of-pocket expenses Executive incurs in connection with any such cooperation (excluding forgone wages, salary, or
other compensation) and will make reasonable efforts to accommodate Executive’s scheduling needs. 

  
 3. 

 8.    GENERAL
PROVISIONS. 
 8.1    Notices. Any notices
required hereunder to be in writing shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient,
and if not, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to Executive at Executive’s address as listed on the Company payroll, or at such
other address as the Company or Executive may designate by ten (10) days advance written notice to the other. 

8.2    Severability. Whenever possible, each provision of this Agreement will be interpreted in such
manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or
unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provisions had never been contained herein.

 8.3    Survival. Provisions of this Agreement which by their terms must survive the
termination of this Agreement in order to effectuate the intent of the parties will survive any such termination, whether by expiration of the term, termination of Executive’s employment, or otherwise, for such period as may be appropriate
under the circumstances. 
 8.4    Dispute Resolution. To ensure the rapid and economical
resolution of disputes that may arise in connection with Executive’s employment with and services for the Company and its Affiliates, Executive and the Company both agree that any and all disputes, claims, or causes of action, in law or equity,
including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, Executive’s employment with and services for the Company and its Affiliates, or the
termination of Executive’s employment with and services for the Company and its Affiliates, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent
permitted by law, by final, binding and confidential arbitration conducted in San Diego, California by JAMS, Inc. (“JAMS”) or its successors, before a single arbitrator under JAMS’ then applicable rules and procedures
for employment disputes (available upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/). Both Executive and the Company acknowledge that by agreeing to this arbitration procedure, Executive
each waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether by Executive or the Company, must be brought
in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not
consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law
or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This Section shall not apply to any action or claim that cannot be subject to mandatory
arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as
amended, to the extent such claims are not permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the
“Excluded Claims”). In the event Executive intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to
mandatory arbitration. Executive will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this Agreement shall be decided by the arbitrator. Likewise,
procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. In any such proceeding, the arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of
the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for
the award, and the arbitrator’s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that Executive or the Company would be entitled to seek in a court of law. Nothing in this
Agreement is intended to 

  
 4. 

 
prevent either the Company or Executive from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. The
Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law, and shall pay the arbitrator’s fees and any other fees or costs unique to arbitration. Any awards or orders in such
arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. 

8.5    Waiver. If either party should waive any breach of any provisions of this Agreement, it shall
not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement. 

8.6    Complete Agreement. This Agreement constitutes the entire agreement between Executive and the
Company with regard to the subject matter hereof. This Agreement is the complete, final, and exclusive embodiment of their agreement with regard to this subject matter and supersedes any prior oral discussions or written communications and
agreements, including without limitation, the Prior Agreement. This Agreement is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in writing
signed by Executive and an authorized officer of the Company. The parties have entered into a separate Proprietary Information Agreement and have or may enter into separate agreements related to equity. These separate agreements govern other aspects
of the relationship between the parties, have or may have provisions that survive termination of Executive’s employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable
according to their terms without regard to the enforcement provision of this Agreement. 

8.7    Amendment. This Agreement may not be amended or modified except in a written instrument signed
by both Executive and the Board, with the exception of those changes expressly reserved to the Company’s discretion. 

8.8    Counterparts. This Agreement may be executed in separate counterparts, any one of which need
not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement. The parties agree that facsimile and scanned image copies of signatures will suffice as original signatures. 

8.9    Headings. The headings of the sections hereof are inserted for convenience only and shall not
be deemed to constitute a part hereof nor to affect the meaning thereof. 
 8.10    Successors and
Assigns. The Company shall assign this Agreement and its rights and obligations hereunder in whole, but not in part, to any Company or other entity with or into which the Company may hereafter merge or consolidate or to which the Company may
transfer all or substantially all of its assets, if in any such case said Company or other entity shall by operation of law or expressly in writing assume all obligations of the Company hereunder as fully as if it had been originally made a party
hereto, but may not otherwise assign this Agreement or its rights and obligations hereunder. The Executive may not assign or transfer this Agreement or any rights or obligations hereunder, other than to his estate upon his death. 

8.11    Choice of Law. All questions concerning the construction, validity and interpretation of this
Agreement will be governed by the laws of the State of California. 
 8.12    Interpretation. Any
ambiguity in this Agreement shall not be construed against either party as the drafter. 

  
 5. 

 IN WITNESS WHEREOF, the
parties have executed this Amended and Restated Executive Employment Agreement on the day and year first written above. 
  

			
	Poseida Therapeutics, Inc.
	By:	 	 /s/ Harry Leonhardt, Esq.

	Name:	 	Harry Leonhardt, Esq.
	Title:	 	General Counsel, Chief Compliance Officer
& Corporate Secretary
	
	Executive:
	 /s/ Mark Gergen

	Mark Gergen

  
 6. 

 Exhibit A 

PROPRIETARY INFORMATION AND INVENTION ASSIGNMENT AGREEMENTEX-10.2

 Exhibit 10.2 

POSEIDA THERAPEUTICS, INC. 

SEVERANCE AND CHANGE IN CONTROL PLAN 

AMENDED AND RESTATED PARTICIPATION AGREEMENT 

 

	Name:	 Mark Gergen 

  

	Section 1.	 ELIGIBILITY. 

You have been designated as eligible to participate in the Poseida Therapeutics, Inc. Severance and Change in Control Plan (the
“Plan”), a copy of which is attached to this Amended and Restated Participation Agreement (the “A&R Participation Agreement”). Capitalized terms not explicitly defined in this A&R Participation
Agreement but defined in the Plan shall have the same definitions as in the Plan. You will receive the benefits set forth below if you meet all the eligibility requirements set forth in the Plan, including, without limitation, executing the required
Release within the applicable time period set forth therein and allowing such Release to become effective in accordance with its terms. Notwithstanding the schedule for provision of benefits as set forth below, the schedule and timing of payment of
any benefits under this Participant Agreement is subject to any delay in payment that may be required under Section 5 of the Plan. 
  

	Section 2.	 CHANGE IN CONTROL SEVERANCE
BENEFITS. 

 If you are terminated in a Covered Termination that occurs during the Change in Control
Period, you will receive the severance benefits set forth in this Section 2. All severance benefits described herein are subject to standard deductions and withholdings. 

(a)    Base Salary. You shall receive a cash payment in an amount equal to 18
months (the “Severance Period”) of payment of your Base Salary. The Base Salary payment will be paid to you in a lump sum cash payment no later than the second regular payroll date following the later of (i) the
effective date of the Release or (ii) the Closing, but in any event not later than March 15 of the year following the year in which your Separation from Service occurs. 

(b)    Bonus Payment. You will be entitled to the annual target cash bonus
established for you, if any, pursuant to the annual performance bonus or annual variable compensation plan established by the Board of Directors or Committee (or any authorized committee or designee thereof) for the year in which your Covered
Termination occurs. If at the time of the Covered Termination you are eligible for the annual target cash bonus for the year in which the Covered Termination occurs, but the target percentage (or target dollar amount, if specified as such in the
applicable bonus plan) for such bonus has not yet been established for such year, the target percentage shall be the target percentage established for you for the preceding year (but adjusted, if necessary for your position for the year in which the
Covered Termination occurs). For the avoidance of doubt, the amount of the annual target bonus to which you are entitled under this Section 2(b) will be calculated (1) assuming all articulated performance goals for such bonus (including,
but not limited to, corporate and individual performance, if applicable), for the year of the Covered Termination was achieved at target levels; (2) as if you had provided services for the entire year for which the bonus relates; and
(3) ignoring any reduction in your Base Salary that would give rise to your right to resignation for Good Reason (such bonus to which you are entitled 

 under this Section 2(b), the “Annual Target Bonus Severance Payment”). The
Annual Target Bonus Severance Payment shall be paid in a lump sum cash payment no later than the second regular payroll date following the later of (i) the effective date of the Release or (ii) the Closing, but in any event not later than
March 15 of the year following the year in which your Separation from Service occurs. 

(c)    Payment of Continued Group Health Plan Benefits. If you timely elect
continued group health plan continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) following your Covered Termination date, the Company shall pay directly to the carrier the full
amount of your COBRA premiums on behalf of you for your continued coverage under the Company’s group health plans, including coverage for your eligible dependents, until the earliest of (i) the end of the Severance Period following the
date of your Covered Termination, (ii) the expiration of your eligibility for the continuation coverage under COBRA, or (iii) the date when you become eligible for substantially equivalent health insurance coverage in connection with new
employment (such period from your termination date through the earliest of (i) through (iii), the “COBRA Payment Period”). Upon the conclusion of such period of insurance premium payments made by the Company, you will be
responsible for the entire payment of premiums (or payment for the cost of coverage) required under COBRA for the duration of your eligible COBRA coverage period, if any. For purposes of this Section, (1) references to COBRA shall be deemed to
refer also to analogous provisions of state law and (2) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan,
which amounts, if any, are your sole responsibility. You agree to promptly notify the Company as soon as you become eligible for health insurance coverage in connection with new employment or self-employment. 

Notwithstanding the foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium
benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then in lieu of paying COBRA premiums directly to the carrier on your
behalf, the Company will instead pay you on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the value of your monthly COBRA premium for the first month of COBRA coverage, subject to applicable
tax withholding (such amount, the “Special Severance Payment”), such Special Severance Payment to be made without regard to your election of COBRA coverage or payment of COBRA premiums and without regard to your continued
eligibility for COBRA coverage during the COBRA Payment Period. Such Special Severance Payment shall end upon expiration of the COBRA Payment Period. 

(d)    Equity Acceleration. The vesting and exercisability of each outstanding
unvested stock option and other stock award, as applicable, that you hold covering Company common stock as of the date of your Covered Termination (each, an “Equity Award”) that is subject to time-vesting shall be accelerated
in full and any reacquisition or repurchase rights held by the Company in respect of Company common stock issued pursuant to any time-vesting Equity Award granted to you shall lapse in full. To the extent your Covered Termination occurs prior to the
Change in Control, the acceleration set forth in this Section 2(d) shall be contingent and effective upon the Change in Control and your Equity Awards will remain outstanding following your Covered Termination to give effect to such
acceleration as necessary. For the avoidance of doubt, any Equity Awards subject to performance-vesting shall vest and become exercisable according to their individual award agreements. 

Section 3.          
NON-CHANGE IN CONTROL SEVERANCE BENEFITS. If you are terminated in a Covered Termination that occurs at a time that is not during the Change
in Control Period, you will receive: 
 (a)    the base salary cash payment described in Section 2(a) above,
but the Severance Period for purposes of calculating such benefits shall be 12 months; and 
 (b)    the COBRA
benefits described in Section 2(c) above, but the Severance Period for purposes of calculating such benefits shall be 12 months. 
 You shall not be
eligible to receive any other benefits under the Plan except as described in Section 2(a) and Section 2(c) above. 
 For the avoidance of doubt, in no
event shall you be entitled to benefits under both Section 2 and this Section 3. If you are eligible for severance benefits under both Section 2 and this Section 3, you shall receive the benefits set forth in Section 2 and
such benefits shall be reduced by any benefits previously provided to you under Section 3. 

Section 4.          CHANGE
IN CONTROL ACCELERATION UPON ACQUIROR’S FAILURE TO ASSUME, CONTINUE OR
SUBSTITUTE. If (i) in connection with a Change in Control, any outstanding unvested Equity Award that you hold will not be assumed or continued by the successor or acquiror entity (or its parent company) in
such Change in Control or substituted for a similar award of the successor or acquiror entity (or its parent company) (a “Terminating Award”) and (ii) your continued employment with the Company has not terminated as of
immediately prior to the effective time of such Change in Control, then you will become vested, with respect to any then unvested portion of such Terminating Award, effective immediately prior to, but subject to the consummation of such Change in
Control. With respect to any such outstanding Terminating Award that is subject to performance-vesting, unless otherwise provided in the individual grant notice and award agreement evidencing such award, such performance-vesting award will
accelerate vesting at 100% of the target level. For the avoidance of doubt, the benefits under this Section 4 are contingent on a Change in Control and do not require your Covered Termination or other termination of service. In addition, you
may be eligible for benefits under this Section 4 in addition to benefits under Section 2 or Section 3 and in such case, you shall receive benefits under both sections, without duplication. 

 

	Section 5.	 ACKNOWLEDGEMENTS; INTERACTION WITH PRIOR
BENEFITS. 

 As a condition to participation in the Plan, you hereby acknowledge each of the following:

 (a)    The benefits that may be provided to you under this A&R
Participation Agreement are subject to certain reductions and termination under Section 2 and Section 3 of the Plan. 

 (b)    Your eligibility for
and receipt of any severance benefits to which you may become entitled as described in Section 2 or Section 3 above is expressly contingent upon your execution of and compliance with the terms and conditions of the Plan, the Release and
the Confidentiality Agreement. Severance benefits under this A&R Participation Agreement shall immediately cease in the event of your violation of the provisions of Confidentiality Agreement or any other written agreement with the Company. 

(c)    As further described in Section 2(c) of the Plan, this A&R
Participation Agreement and the Plan supersede and replace that certain Participation Agreement by and between you and the Company, signed on July 17, 2020 and any other change in control or severance benefits previously provided to you, including
but not limited to any benefits under your employment or other written agreement or plan, and by executing below you expressly agree to such treatment. 

To accept the terms of this A&R Participation Agreement and participate in the Plan, please sign and date this A&R Participation Agreement in the
space provided below. 
  

			
	Poseida Therapeutics, Inc.
		
	By:	 	 /s/ Harry Leonhardt, Esq.

	Name:	 	 Harry Leonhardt, Esq.

	Title:	 	 General Counsel, Chief Compliance Officer & Corporate Secretary

  

			
	Eligible Employee
	
	 /s/ Mark Gergen

Mark Gergen

		
	Date:	 	 February 1, 2022

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]